JP4264135B2 - ドーパミンd▲下4▼レセプターアンタゴニストとしての2,4―ジアミノピリミジン誘導体 - Google Patents
ドーパミンd▲下4▼レセプターアンタゴニストとしての2,4―ジアミノピリミジン誘導体 Download PDFInfo
- Publication number
- JP4264135B2 JP4264135B2 JP54053697A JP54053697A JP4264135B2 JP 4264135 B2 JP4264135 B2 JP 4264135B2 JP 54053697 A JP54053697 A JP 54053697A JP 54053697 A JP54053697 A JP 54053697A JP 4264135 B2 JP4264135 B2 JP 4264135B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- alk
- piperidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CCNN(CC1)CCC1N(*)c1nc(N(*)*I)ccn1 Chemical compound CCNN(CC1)CCC1N(*)c1nc(N(*)*I)ccn1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201283.7 | 1996-05-10 | ||
EP96201283 | 1996-05-10 | ||
PCT/EP1997/002506 WO1997043279A1 (en) | 1996-05-10 | 1997-05-02 | 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000512623A JP2000512623A (ja) | 2000-09-26 |
JP4264135B2 true JP4264135B2 (ja) | 2009-05-13 |
Family
ID=8223971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54053697A Expired - Lifetime JP4264135B2 (ja) | 1996-05-10 | 1997-05-02 | ドーパミンd▲下4▼レセプターアンタゴニストとしての2,4―ジアミノピリミジン誘導体 |
Country Status (19)
Country | Link |
---|---|
US (2) | US6159982A (de) |
EP (1) | EP0912552B1 (de) |
JP (1) | JP4264135B2 (de) |
KR (1) | KR100462524B1 (de) |
CN (1) | CN1134431C (de) |
AT (1) | ATE264853T1 (de) |
CA (1) | CA2253429C (de) |
CZ (1) | CZ289250B6 (de) |
DE (1) | DE69728768T2 (de) |
ES (1) | ES2221052T3 (de) |
HU (1) | HUP9903445A3 (de) |
IL (1) | IL126969A (de) |
MY (1) | MY116114A (de) |
NO (1) | NO317179B1 (de) |
NZ (1) | NZ332308A (de) |
PL (1) | PL187769B1 (de) |
TW (1) | TW504510B (de) |
WO (1) | WO1997043279A1 (de) |
ZA (1) | ZA974050B (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9811557A (pt) * | 1997-08-15 | 2000-08-22 | Pfizer Prod Inc | Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol |
US6288230B1 (en) | 1998-09-29 | 2001-09-11 | Neurogen Corporation | 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
WO2000018763A2 (en) * | 1998-09-29 | 2000-04-06 | Neurogen Corporation | 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
US6284759B1 (en) | 1998-09-30 | 2001-09-04 | Neurogen Corporation | 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands |
US6107313A (en) * | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
KR100394083B1 (ko) * | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
IL157363A0 (en) * | 2001-02-16 | 2004-02-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
EP1361875A2 (de) * | 2001-02-16 | 2003-11-19 | Aventis Pharmaceuticals Inc. | Neue heterocyclische amide-derivate und ihre verwendung als dopamine d3-rezeptor-liganden |
IL157254A0 (en) * | 2001-02-23 | 2004-02-19 | Merck & Co Inc | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists |
US20050222186A1 (en) * | 2002-06-14 | 2005-10-06 | Altana Pharma Ag | Substituted diaminopyrimidines |
WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
US7196928B2 (en) * | 2005-04-05 | 2007-03-27 | Sandisk Corporation | Compensating for coupling during read operations of non-volatile memory |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
RS52451B (en) | 2006-11-01 | 2013-02-28 | Purdue Pharma Lp | PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE |
JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
MX2009011415A (es) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion. |
JP5431306B2 (ja) | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 高速解離性ドパミン2受容体アンタゴニストとしてのチア(ジア)ゾール |
RU2480462C2 (ru) * | 2007-04-23 | 2013-04-27 | Янссен Фармацевтика Н.В. | Производные пиридина, используемые в качестве быстро диссоциирующихся антагонистов допаминовых рецепторов 2 |
JP5457450B2 (ja) | 2008-07-31 | 2014-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 迅速解離性ドーパミン2受容体拮抗薬としてのピペラジン−1−イル−トリフルオロメチル−置換−ピリジン |
KR20120114355A (ko) * | 2010-01-13 | 2012-10-16 | 글락소스미스클라인 엘엘씨 | 화합물 및 방법 |
MA53944A (fr) | 2014-08-28 | 2021-08-25 | Asceneuron Sa | Inhibiteurs de la glycosidase |
CN106243088B (zh) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
EP3419971B1 (de) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase-inhibitoren |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
AU2017222962B2 (en) | 2016-02-25 | 2021-03-25 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
US11542248B2 (en) * | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
EP3672959A1 (de) * | 2017-08-24 | 2020-07-01 | Asceneuron SA | Lineare glycosidase-inhibitoren |
EP3684361A4 (de) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | Substituierte inhibitoren von menin-mll und verfahren zur verwendung |
WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
GB9216298D0 (en) * | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
-
1997
- 1997-05-01 TW TW086105766A patent/TW504510B/zh active
- 1997-05-02 WO PCT/EP1997/002506 patent/WO1997043279A1/en active IP Right Grant
- 1997-05-02 IL IL12696997A patent/IL126969A/xx not_active IP Right Cessation
- 1997-05-02 AT AT97923914T patent/ATE264853T1/de not_active IP Right Cessation
- 1997-05-02 KR KR10-1998-0707915A patent/KR100462524B1/ko not_active IP Right Cessation
- 1997-05-02 DE DE69728768T patent/DE69728768T2/de not_active Expired - Lifetime
- 1997-05-02 CA CA002253429A patent/CA2253429C/en not_active Expired - Fee Related
- 1997-05-02 US US09/180,364 patent/US6159982A/en not_active Expired - Lifetime
- 1997-05-02 NZ NZ332308A patent/NZ332308A/xx unknown
- 1997-05-02 CN CNB971945160A patent/CN1134431C/zh not_active Expired - Lifetime
- 1997-05-02 ES ES97923914T patent/ES2221052T3/es not_active Expired - Lifetime
- 1997-05-02 HU HU9903445A patent/HUP9903445A3/hu unknown
- 1997-05-02 JP JP54053697A patent/JP4264135B2/ja not_active Expired - Lifetime
- 1997-05-02 CZ CZ19983627A patent/CZ289250B6/cs not_active IP Right Cessation
- 1997-05-02 EP EP97923914A patent/EP0912552B1/de not_active Expired - Lifetime
- 1997-05-02 PL PL97329850A patent/PL187769B1/pl not_active IP Right Cessation
- 1997-05-07 MY MYPI97002019A patent/MY116114A/en unknown
- 1997-05-09 ZA ZA974050A patent/ZA974050B/xx unknown
-
1998
- 1998-11-09 NO NO19985228A patent/NO317179B1/no unknown
-
2000
- 2000-09-22 US US09/667,458 patent/US6395742B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IL126969A (en) | 2003-01-12 |
TW504510B (en) | 2002-10-01 |
CA2253429C (en) | 2006-08-08 |
US6395742B1 (en) | 2002-05-28 |
NO317179B1 (no) | 2004-09-06 |
CN1218466A (zh) | 1999-06-02 |
ZA974050B (en) | 1998-11-09 |
WO1997043279A1 (en) | 1997-11-20 |
PL329850A1 (en) | 1999-04-12 |
ATE264853T1 (de) | 2004-05-15 |
EP0912552A1 (de) | 1999-05-06 |
ES2221052T3 (es) | 2004-12-16 |
IL126969A0 (en) | 1999-09-22 |
US6159982A (en) | 2000-12-12 |
AU708344B2 (en) | 1999-08-05 |
HUP9903445A3 (en) | 2002-01-28 |
KR20000005228A (ko) | 2000-01-25 |
CN1134431C (zh) | 2004-01-14 |
HUP9903445A2 (hu) | 2000-05-28 |
CZ289250B6 (cs) | 2001-12-12 |
NZ332308A (en) | 1999-08-30 |
AU2956197A (en) | 1997-12-05 |
EP0912552B1 (de) | 2004-04-21 |
NO985228D0 (no) | 1998-11-09 |
CZ362798A3 (cs) | 1999-02-17 |
MY116114A (en) | 2003-11-28 |
CA2253429A1 (en) | 1997-11-20 |
NO985228L (no) | 1999-01-11 |
JP2000512623A (ja) | 2000-09-26 |
KR100462524B1 (ko) | 2005-06-13 |
PL187769B1 (pl) | 2004-10-29 |
DE69728768T2 (de) | 2005-04-28 |
DE69728768D1 (de) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4264135B2 (ja) | ドーパミンd▲下4▼レセプターアンタゴニストとしての2,4―ジアミノピリミジン誘導体 | |
CZ20012657A3 (cs) | Piperidinové, tetrahydropyridinové a piperazinové deriváty | |
JP3237759B2 (ja) | アルキルアミノベンゾチアゾールおよび―ベンゾキサゾール誘導体 | |
JP2020523330A (ja) | シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト | |
JP4166824B2 (ja) | ピペラジン誘導体および5−ht1a拮抗薬としてのそれらの使用 | |
TW210338B (de) | ||
HU227799B1 (hu) | Tachikinin-antagonista hatású N-acil-2-szubsztituált-4-(benzimidazolil-vagy imidazo-piridinil-szubsztituált csoport)-piperidin-származékok | |
JP2001515899A (ja) | テトラヒドロガンマ−カルボリン類 | |
JP3953097B2 (ja) | N−置換ピペリジニル二環式ベンゾエート誘導体 | |
JPH0699420B2 (ja) | 水素添加された1−ベンゾオキサシクロアルキルピリジンカルボン酸化合物,その製造方法及び該化合物を含む医薬製剤 | |
JP2006503056A (ja) | ヒスタミンh3受容体アンタゴニスト、その製造および治療用使用 | |
JP3980056B2 (ja) | プロキネティック オキサジアゾール | |
AU708344C (en) | 2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonists | |
JP3995404B2 (ja) | ピリミジン誘導体またはその塩 | |
US5166341A (en) | 6-amino-1,4-hexahydro-1H-diazepine derivatives | |
JP4042566B2 (ja) | ピペリジン化合物およびその医薬用途 | |
JPH09291090A (ja) | ピペリジノンおよびホモピペリジノン誘導体 | |
JP2003514764A (ja) | 5−ht1受容体アゴニストとしてのアリール−{4−フルオロ−4−[(2−ピリジン−2−イルエチルアミノ)メチル]ピペリジン−1−イル)メタノン誘導体 | |
JPH05320157A (ja) | 1−置換アルキルキノキサリン誘導体およびその用途 | |
JPH04210970A (ja) | ベンズアミド誘導体及びその中間体 | |
JP2016106072A (ja) | プロペラン誘導体 | |
MXPA00010454A (en) | Indolyl derivatives as serotonergic agents | |
AU2002221576A1 (en) | 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders | |
CZ91997A3 (en) | Derivatives of phenyl-oxo-alkyl-(4-piperidinyl)benzoates | |
JP2010539216A (ja) | M1受容体にて活性を有する化合物および医薬としてのそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A625 | Written request for application examination (by other person) |
Free format text: JAPANESE INTERMEDIATE CODE: A625 Effective date: 20040109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080108 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090210 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090216 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140220 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |